Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

Journal of the National Cancer Institute

Volumn 85, Issue 16, 1993, Pages 1327-1333

  Baselga, Jose ^a   Norton, Larry ^a   Masui, Hideo ^a   Pandiella, Atanasio ^b   Coplan, Keren ^a   Miller, Wilson H ^a   Mendelsohn, John ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; EXPERIMENTAL NEOPLASM; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RECEPTOR BLOCKING; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ANIMAL; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMAN; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0027290650     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/85.16.1327     Document Type: Article

References (31)

1. Derynck R, Goeddel DV, Ullrich A, et al: Synthesis of messenger RNAs for transforming growth factors a and ft and the epidermal growth factor receptor by human tumors. Cancer Res 47:707-712, 1987
2. Nicholson S, Richard J, Sainsbury C, et al: Epidermal Growth Factor (EGFr); results of a 6 years follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63:146-150, 1991
3. Neal DE, Bennett MK, Hall RR, et al: Epidermal-growth-factor receptors in human bladder cancer Comparison of invasive and superficial tumours. Lancet 1:366-368, 1985
4. Hendler FJ, Shum-Siu A, Oechsli M, et al: Increased EGF-R1 binding predicts a poor survival in squamous tumors. Cancer Cells 7:347-351, 1989
5. Rosenthal A, Lindquist PB, Bringman TS, et al: Expression in rat fibroblasts of a human transforming growth factor-a cDNA results in transformation. Cell 46:301-309, 1986
6. Di Marco E, Pierce JH, Fleming TP, et al: Autocrine interaction between TGF-a and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4:831-838, 1989
7. Kawamoto T, Sato JD, Le A, et al: Growth stimulation of A431 cells by epidermal growth factor: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A 80:1337-1341, 1983
8. Sato D, Kawamoto T, Le AD, et al: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511-529, 1983
9. Gill GN, Kawamoto T, Cochet C, et al: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259:7755-7760, 1984
10. Sunada H, Yu P, Peacock JS, et al: Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J Cell Physiol 142:284-292, 1990
11. Markowitz SD, Molkentin K, Gerbic C, et al: Growth stimulation by coexpression of transforming growth factor-a and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. J Clin Invest 86:356-362, 1990
12. Ennis BW, Valverius EM, Bates SE, et al: Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 3:1830-1838, 1989
13. Ciardiello F, McGeady ML, Kim N, et al: TGFa expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene and overexpression of the TGFa cDNA leads to transformation. Cell Growth Differ I:407^f20, 1990
14. Masui H, Kawamoto T, Sato JD, et al: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002-1007, 1984
15. Mendelsohn J: Potential clinical applications of anti-EGF receptor monoclonal antibodies. Cancer Cells 7:359-362, 1989
16. Valverius EM, Bates SE, Stampfer ME, et al: Transforming growth factor-a production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. Mol Endocrinol 3:203-214, 1989
17. Aboud-Pirak E, Hurwitz E, Pirak ME, et al: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605-1611, 1988 Tritton TR: Cell surface actions of Adriamycin. Pharmac Ther 49:293-309, 1991
18. Marks Dl, Fox RM: DNA damage, poly (ADP-ribosyl)ation and apoplolic cell death as a potential common pathway of cytotoxic drug action. Biochem Pharmacol 42:18591867, 1991
19. Barry MA, Behnke CA, Eastman A: Activation of programmed cell death (apop- tosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 40:2353-2362, 1990
20. Williams GT, Smith CA, Spooncer E, et al: Haemopoietic colony stimulating factors promote cell survival by suppressing apop- tosis. Nature 343:76-79, 1990
21. Zuckier G, Tritton TR: Adriamycin causes up regulation of epidermal growth factor receptor in actively growing cells. Exp Cell Res 148:155-161, 1983
22. Hanauske AR, Osborne CK, Chamness GC, et al: Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol 23:545-551, 1987
23. Reig L, Colburn P, Sato G, et al: Approaches to chemotherapy using the athymic nude mice. In Proceedings of the Symposium on the Use of Athymic (Nude) Mice in Cancer Research (Houchens DP, Ovejera AA, eds). New York: Gustav Fischer, 1978, pp 123-131
24. Masui H, Moroyama T, Mendelsohn J: Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different iso-types. Cancer Res 46:5592-5598, 1986
25. Hancock MC, Langton BC, Chan T, et al: A monoclonal antibody against the c-crbB-2 protein enhances the cytotoxicity of c/j-diamminedichloroplatinum against human breast cancer and ovarian tumor cell lines. Cancer Res 51:4575-4580, 1991
26. Baselga J, Miller W, Norton L, et al: Modulation of epidermal growth factor receptor (EGFR)/transforming growth fac- lor-a (TGF-a) pathway by adriamycin (ADR). Proceedings of the American Association of Cancer Research 33:2947, 1992
27. Cullen KJ, Smith HS, Hill S, et al: Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions. Cancer Res 51:49784985, 1991
28. Panneerselvam M, Bredehorst R, Vogel CW: Immobilized doxorubicin increases the complement susceptibility of human melanoma cells by protecting complement component C3b against inactivation. Proc Natl Acad Sci USA 83:91449148, 1986
29. Yang HM, Reisfeld RA: Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci U S A 85:1189-1193, 1988
30. Divgi CR, Welt S, Kris M, et al: Phase I and imaging trial of indium Ill-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Nall Cancer Inst 83:97-104, 1991
31. 1Mln. Proc ASCO 12:368, 1993